|
hallo leute, nach soviel pro`s und co`s , mal was handfestes. falls das schon jemand gepostet hatte, sorry ... meine persönliche einschätzung : für ein paar falten weniger geben frauen (bzw. ihre zahlenden männer) alles ! siehe laserbehandlung, fettunterspritzung etc. was sind da die preise ? was sind die preise für eine hochwirksame creme ? Joop ist m.E. kein dummerchen, der schaut sich genau an, wofür er seinen namen hergibt. und hier die testergebnisse : Sangui BioTech Int`l Inc.: Study demonstrates effectiveness of oxygen carriers in skin treatment Wed, 27 March 2002 03:48 am Published by: Dr. Sieglinde Borchert Company-Shortcut: STX Get a printer-friendly version here Rating: 4/10 Santa Ana, California – 14 March 2002 – Sangui BioTech International, Inc., (NASDAQ OTC BB: SGBI; WKN 906 757) announced today the results of a study regarding the effectiveness of treating the skin with oxygen carriers, which are developed and modified into hemoglobin emulsions* by its wholly-owned subsidiary SanguiBioTech AG, based in Witten, Germany. The three key results of the study are: 1) Increased skin smoothness and a reduction of wrinkles 2) Demonstrated penetration into the horny layers of the skin 3) Increase in the oxygen partial pressure in the skin epithelium (= supply of bio-available oxygen in the vital epithelial cells is increased) Increased skin smoothness and reduced wrinkles was measured with 11 female test subjects, who received 12 treatments with the hemoglobin emulsions in an 8-week period. The smoothness of the skin on the forehead increased on average by 39 percent, at the corners of the eyes by 74 percent and at the corners of the mouth by 72 percent. Wrinkles in the skin were reduced on the forehead on average by 29 percent, at the corners of the eyes by 17 percent and at the corners of the mouth by 43 percent. These results are all the more remarkable since the final measurements were taken just one week after the last treatment. The level of penetration of the oxygen carriers was demonstrated using a pig ear skin model using two measuring methods: both the photometric measurement of the hemoglobin and the gravimetric measurement of the emulsion (i.e. of the hemoglobin including the carrier) in the individual layers of the stratum corneum demonstrated that the oxygen carriers were transported into the horny layer up to a depth of approxiamtely 12 micrometres. "This remarkable, exceptional level of penetration into the horny layer constitutes a huge success for the method we developed for introducing hemoglobin preparations into the skin", stressed project leader Dr. Alexander Teslenko. "This means that a key requirement has been created for the oxygen carriers to demonstrate their regenerative effectiveness in the outer skin cells." The increase in the oxygen partial pressure of the skin epithelium, i.e. the improved supply of the epithelial cells with oxygen, has been demonstrated on forearm skin with comparative measurements of treated and non-treated sections. "These results bring us a significant step closer to market maturity for our hemoglobin emulsions. The fundamental proof of their effectiveness forms the basis for further development and differentiation of several preparation compounds for various areas of application in the skin-care cosmetics", said Prof. Dr. Dr. Wolfgang Barnikol highlighting the importance of the study for the planned market launch. Prof. Barnikol will be explaining the results of the study mentioned here, and the way the oxygen carriers work, to trade visitors in a presentation at "Beauty International 2002", the international trade fair in Düsseldorf for the professional cosmetics industry, as part of the workshop entitled "Innovations in cosmetics" (Saturday, 23 March 2002, 15:30-17:30, Düsseldorf Trade Fair (Messe Düsseldorf), CCD East (CCD-Ost), 1st floor). * The oxygen carriers by SanguiBioTech AG are obtained from hemoglobin and can be applied directly to the skin with suitable emulsions. Under normal physiological conditions, healthy skin takes up oxygen both internally through the bloodstream and externally. Approximately half the oxygen required gets into the active cells of the epidermis via the surrounding air. This is where the concept from SanguiBioTech AG comes into play: the basic idea behind the method of operation consists in the mechanism of facilitated oxygen diffusion. Worked into the skin`s outer cell layers, the oxygen carriers enhance the diffuse flow of oxygen externally and so improve the "skin`s breathing" so to speak. Contact details: Birgit Strautz SanguiBioTech AG Tel: +49 (0)2302 915 200 Fax: +49 (0)2302 915 201 strautz@sangui.de /> Dr. Sieglinde Borchert, Chief Operating Officer Sangui BioTech International Inc. Tel: +49 (0)2302 915 200 Fax: +49 (0)2302 915 201 borchert@sangui.de /> http://www.sangui.de /> This news release includes statements, other than historical fact, that may be deemed forward-looking. These statements may be accompanied by words such as “believe,” “estimate,” “project,” “expect,” “anticipate,” or “predict” that conveys the uncertainty of future events or outcomes. These statements are based on assumptions that the Company believes are reasonable; however, many factors could cause the Company’s actual results in the future to differ materially from the forward-looking statements made herein and in any other documents or oral presentations made by, or on behalf of, the Company. Important factors which could cause actual results to differ materially from those in forward-looking statements include, among others, the ability to obtain additional financing, which is not assured; rapid technological developments and changes; problems in developments of the Company’s products; price and product competition by competitors; general economic conditions; and factors discussed in the Company’s SEC filings. Shareholders are cautioned that the forward-looking statements are not guarantees of future performance and that developments different from those projected in the forward-looking statements can be expected. Sangui does not intend (and is not legally obligated) to update publicly any forward-looking statements. http://www.startupx.com/?Type=News&NewsID=0000000011 |
|
| aus der Diskussion: | Sangui die Sensation |
| Autor (Datum des Eintrages): | smirnoff_gurgler (15.11.03 14:34:25) |
| Beitrag: | 156 von 960 (ID:11339109) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |